Researchers at the Department of Cell and Molecular Biology, Karolinska Institutet have captured the first detailed molecular ...

This article explores how challenges such as sequence optimization, immune activation and off-target effects are being ...

The Scottish technology firm has raised a second tranche of investment to further grow its business in the field of early disease detection ...

Renaissance BioScience’s novel RNA production and delivery technology receives Mexican patent: Vancouver, Canada Monday, December 8, 2025, 17:00 Hrs [IST] Renaissance BioScience ...

Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseasesQfitlia, the first antithrombin-lowering therapy for hemophilia, ...

The Allan Labor Government is supporting Melbourne researchers who have discovered a groundbreaking RNA treatment targeting rare childhood diseases ...

Cell free RNA diagnostics market is projected to reach US$ 204.5 Mn by 2035, expanding at a CAGR of 14.5% from 2025 to 2035 ...

Industrialized, small batch, and individual RNA therapeutics become practical with “in-a-box” manufacturing technology.

This hot biotech stock could have a lot more room to run.

The test is now ordered by breast surgeons or radiation oncologists in more than 85% of the top 50 U.S. cancer centers.

Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for applications across infectious disease, immunology, and other therapeutic areas, and ...